share_log

6-K: Gsk Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

SEC ·  Dec 20, 2024 15:30

Summary by Futu AI

GSK announced that the FIRST-ENGOT-OV44 phase III trial met its primary endpoint, demonstrating significant progression-free survival improvement in first-line advanced ovarian cancer treatment. The trial evaluated the combination of Jemperli (dostarlimab) with platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, versus standard treatment.The study involved 1,331 patients with stage III or IV nonmucinous epithelial ovarian cancer. While the primary endpoint of progression-free survival showed statistically significant improvement, the key secondary endpoint of overall survival did not meet statistical significance. The safety profile remained consistent with known profiles of individual agents.Ovarian cancer, the eighth most common cancer in women worldwide, has an 85% recurrence rate despite initial response to platinum-based chemotherapy. The trial results will be presented at an upcoming scientific meeting and shared with health authorities for further evaluation.
GSK announced that the FIRST-ENGOT-OV44 phase III trial met its primary endpoint, demonstrating significant progression-free survival improvement in first-line advanced ovarian cancer treatment. The trial evaluated the combination of Jemperli (dostarlimab) with platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, versus standard treatment.The study involved 1,331 patients with stage III or IV nonmucinous epithelial ovarian cancer. While the primary endpoint of progression-free survival showed statistically significant improvement, the key secondary endpoint of overall survival did not meet statistical significance. The safety profile remained consistent with known profiles of individual agents.Ovarian cancer, the eighth most common cancer in women worldwide, has an 85% recurrence rate despite initial response to platinum-based chemotherapy. The trial results will be presented at an upcoming scientific meeting and shared with health authorities for further evaluation.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 278

Recommended